1. Short title This Act may be cited as Stop CMV Act of 2024 . 2. Screening of congenital Cytomegalovirus Part A of title XI of the Public Health Service Act is amended by inserting after section 1116 ( 42 U.S.C. 300b–15 ) the following: 1116A. Screening of congenital Cytomegalovirus (a) In general Each hospital or other health care entity caring for infants who are 21 days or less of age (as designated by the Secretary) may administer, or cause to have administered, to every such infant in its care a test for congenital Cytomegalovirus in accordance with this section. (b) Process (1) In general In carrying out this section, the chief executive officer for health in each State may prescribe standards and procedures for the administration of testing under subsection (a), including recording the results of such tests, tracking activities, conducting follow-up reviews, and carrying out educational activities. (2) Dissemination of information In carrying out this section, the chief executive officer for health in each State may prescribe standards and procedures setting forth the manner in which testing information is disseminated to a parent or guardian of the infant to be tested. (3) Failure to prescribe If a State has not prescribed standards and procedures that are approved as provided for in paragraph (4) by the date that is 2 years after the date of enactment of the Stop CMV Act of 2024 , the Discretionary Advisory Committee on Heritable Disorders in Newborns and Children established under section 1111 (referred to in this section as the Advisory Committee ) shall prescribe appropriate standards and procedures which may be implemented by such State. (4) Review and approval The standards and procedures prescribed under this subsection shall be subject to review and approval by the Advisory Committee. In reviewing or prescribing standards and procedures as required under this subsection, the Advisory Committee shall consider standards and procedures adopted in other States with respect to the screening of